On the basis of disclosed annual results, revenue rose from KRW 194.8 billion in 2022 to KRW 261 billion in 2023 (up 34.0%), KRW 350.1 billion in 2024 (up 34.1%), and KRW 536.3 billion in 2025 (up 53.2%). Revenue has grown for three consecutive years from 2023 through 2025.
Operating profit climbed from KRW 65.9 billion in 2022 to KRW 214.4 billion in 2025, and the operating margin moved from 33.8% in 2022 to 35.3% in 2023, 36.0% in 2024 and 40.0% in 2025. In 2025 operating profit grew 70.1%, faster than revenue, so margin improvement supported earnings growth.
Cost of sales as a share of revenue fell from 28.2% in 2024 to 23.3% in 2025 according to Deal Bio reporting, which points to the cost structure behind the higher margin.
Selling, general and administrative expenses, however, rose 57.2% to KRW 196.8 billion in 2025 from KRW 125.2 billion in 2024, offsetting part of that gain.
Net profit attributable to controlling shareholders grew from KRW 40.6 billion in 2022 to KRW 165.1 billion in 2025, a 79.4% rise in 2025, while net profit including non-controlling interests was KRW 168.3 billion, a different figure.
Operating cash flow reached KRW 183.2 billion in 2025, up from KRW 59.4 billion in 2022. Quarterly revenue peaked at KRW 178.7 billion in the second quarter of 2026, and third-quarter revenue of KRW 171.5 billion fell 4.0% from the prior quarter but rose 26.7% year on year.
Third-quarter operating profit of KRW 62.6 billion declined 5.8% from the prior quarter. Net profit attributable to controlling shareholders fell from KRW 56.6 billion in the second quarter to KRW 30 billion in the third quarter. Over the most recent four quarters, that profit totaled KRW 166.7 billion.
The company said first-half 2026 revenue of KRW 324.8 billion and operating profit of KRW 123.8 billion were record first-half results, in a release dated August 7, 2026.